PLK1 and neoplasm: Intravenous injection of PEGylated lipid shells encapsulating plasmid DNA into A375 tumor-bearing mice was found to reduce expression of PLK1 in tumor tissues and provide greater antitumor effects compared to treatment with a lipoplex of plasmid DNA and the commercial agent, Lipofectamine 2000.